Methylprednisolone in the management of post-COVID-19 interstitial lung disease: A randomized trial (STERCOV-ILD).

20260 citationsJournal Article

Authors

Aycan Yüksel · TOBB University of Economics and Technology

Dilek Karadoğan · Recep Tayyip Erdoğan University

Nur Hürsoy · Recep Tayyip Erdoğan University

Tahsin Gökhan Telatar · Recep Tayyip Erdoğan University

Neslihan Köse Kabil · Yalova University

Feride Marım · Dumlupinar University

İlknur Kaya

Abstract

Methylprednisolone improved oxygen saturation, FVC, exercise capacity, and radiological resolution in patients with post-COVID-19 ILD compared to the natural course of the disease.

Topics & Keywords

Long-Term Effects of COVID-19 Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Chronic Obstructive Pulmonary Disease (COPD) Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PubMed

Volume 43, Issue 1, pp. 17022-17022

DOI: 10.36141/svdld.2026.17022

Field-Weighted Citation Impact: 0.00